Welcome to Men's Health Focus.
Please log in or register to view the content of this site.
This website provides free access to a range of men’s health related resources and has been developed by EPG Online with an educational grant and assistance from Bayer HealthCare Pharmaceuticals. The content of this site is intended for doctors and other healthcare professionals.
As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.
Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.
- Testosterone undecanoate can improve sexual function and quality of life in males with type 2 diabetes
- The 82-week BLAST study, which included 190 males age >18 years with T2D, is the largest and longest study to date that investigates the effects of TU therapy in males with T2D
- In contrast with comparative studies, the study was performed by general practitioners in the primary care setting, rather than specialist diabetes centers
- TU significantly improved all IIEF domains versus placebo at 30 weeks, with significant improvements also seen at 18 weeks
- At 30 weeks, improvement with TU versus placebo included erectile function, p=0.005; intercourse satisfaction, p=0.015; sexual desire, p=0.001; orgasm, p=0.004
- For erectile function, there were significant improvements at 18 and 30 weeks for TU versus placebo in males aged ≥60 years
- Improvements in sexual function scores were seen as early as 6 weeks with TU versus placebo
- Sexual function scores continued to improve in the open-label extension to the end of study (weeks 30 to 82)
- An improvement from baseline in erectile function was observed for the active group continuing on TU therapy and the placebo group proceeding to TU therapy (4.31 and 2.97, respectively)
- Health-related quality-of-life measures were significantly improved at 30 weeks for TU versus placebo in males without depression (p=0.02), but not in males with baseline depression
- In a subgroup of males taking phosphodiesterase type 5 inhibitors, there was improvement in erectile function in the open-label phase only
If you are a healthcare professional and would like to gain free access to menshealthfocus.com you must register or login with your EPG Online username and password.
For your information, the menshealthfocus.com website concentrates on the understanding, management and treatment of erectile dysfunction and hypogonadism. The website also provides extensive details on up-coming conferences as well as an extensive library of useful resource.
THIS WEBSITE (www.menshealthfocus.com) IS OWNED AND OPERATED BY EPG HEALH MEDIA (EUROPE) LTD.